Literature DB >> 30389660

Prognostic Models Turn the Heat(IT)up on FLT3ITD -Mutated AML.

Paolo Gallipoli1,2,3, Brian J P Huntly4,2,3.   

Abstract

The presence of internal tandem duplications (ITD) in the FLT3 receptor tyrosine kinase gene have long been known to confer a poor prognosis in patients with acute myeloid leukemia. Now, specific structural features of the ITDs are also suggested to alter patient outcome, including sensitivity to targeted therapies, prompting their evaluation in therapeutic algorithms.See related article by Schwartz et al., p. 573. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30389660      PMCID： PMC6339517          DOI： 10.1158/1078-0432.CCR-18-3146

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  5 in total

Review 1.  The Future of Targeting FLT3 Activation in AML.

Authors:  Mark B Leick; Mark J Levis
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

2.  Genomic Classification in Acute Myeloid Leukemia.

Authors:  Elli Papaemmanuil; Hartmut Döhner; Peter J Campbell
Journal:  N Engl J Med       Date:  2016-09-01       Impact factor: 91.245

3.  Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Authors:  Catherine C Smith; Qi Wang; Chen-Shan Chin; Sara Salerno; Lauren E Damon; Mark J Levis; Alexander E Perl; Kevin J Travers; Susana Wang; Jeremy P Hunt; Patrick P Zarrinkar; Eric E Schadt; Andrew Kasarskis; John Kuriyan; Neil P Shah
Journal:  Nature       Date:  2012-04-15       Impact factor: 49.962

4.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Authors:  Rosemary E Gale; Claire Green; Christopher Allen; Adam J Mead; Alan K Burnett; Robert K Hills; David C Linch
Journal:  Blood       Date:  2007-10-23       Impact factor: 22.113

5.  Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors.

Authors:  Gregory W Schwartz; Bryan Manning; Yeqiao Zhou; Priya Velu; Ashkan Bigdeli; Rachel Astles; Anne W Lehman; Jennifer J D Morrissette; Alexander E Perl; Mingyao Li; Martin Carroll; Robert B Faryabi
Journal:  Clin Cancer Res       Date:  2018-09-04       Impact factor: 12.531
  5 in total
  1 in total

Review 1.  Molecular Landscape of Acute Myeloid Leukemia: Prognostic and Therapeutic Implications.

Authors:  Ludovica Marando; Brian J P Huntly
Journal:  Curr Oncol Rep       Date:  2020-06-01       Impact factor: 5.075
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.